2/16/2024 | GNIG | Moody’s lifts Novartis
|
2/11/2024 | SP | New Issue: JPMorgan prices $250,000 8.5% autocallable contingent interest notes on stocks
|
12/12/2023 | GNIG | DBRS assigns Novartis AA(low)
|
2/10/2023 | GNIG | Moody’s views Novartis positively
|
4/18/2022 | SP | New Issue: Morgan Stanley prices $1.1 million worst-of fixed coupon autocallable RevCons on stocks
|
9/16/2020 | GN | Novartis prices €1.85 billion of sustainability-linked bonds
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
2/12/2020 | IG | New Issue: Novartis Capital details $5 billion of guaranteed notes in four parts
|
2/11/2020 | IG | New Issue: Novartis Capital prices $5 billion of guaranteed notes in four tranches
|
2/11/2020 | IG | Market Commentary: Morning Commentary: Novartis, Sysco, DTE, Oshkosh, Duke on tap; Carrier holds deal calls
|
2/11/2020 | IG | Novartis Capital aims to price fixed-rate notes in four parts
|
10/1/2019 | HY | Market Commentary: Shutterfly prices, Alliant on tap; Bausch, U.S. Steel lower, WeWork sees respite; recent issues active
|
5/28/2019 | SP | Credit Suisse to price buffered return equity notes on stock basket
|
5/6/2019 | SP | Credit Suisse to price buffered return equity notes on stock basket
|
3/22/2019 | BKIG | Alcon lines up $4.2 billion bridge, term, revolving loans for spinoff
|
12/12/2018 | SP | New Issue: Morgan Stanley sells $1 million 10.2% worst-of autocall RevCons on three stocks
|
11/20/2018 | IG | Fitch downgrades Novartis
|
7/19/2018 | IG | Fitch: Novartis ratings unaffected
|
7/2/2018 | IG | Moody’s downgrades Novartis
|
5/10/2018 | SP | New Issue: Morgan Stanley sells $1 million 8% worst-of autocall RevCons on three stocks
|
9/18/2017 | IG | Fitch revises Novartis to negative
|
2/14/2017 | IG | New Issue: Novartis Capital prices $3 billion of guaranteed notes due 2020, 2022, 2027
|
2/14/2017 | IG | Novartis Capital plans sale of three-year, five-year, 10-year notes
|
1/26/2017 | IG | Moody’s: Novartis view to negative
|
11/17/2015 | IG | Market Commentary: High-grade primary sees $12 billion day; Time Warner prices; bonds mixed in secondary
|
11/17/2015 | IG | New Issue: Novartis Capital sells $3 billion of 10-, 30-year senior notes
|
11/17/2015 | IG | Novartis Capital intends to price offering of 10-, 30-year notes
|
9/16/2015 | SPSW | Structured products issuance slow amid short week; $204 million prices ahead of Fed move
|
9/15/2015 | SP | Market Commentary: Morgan Stanley’s $4.28 million RevCons tied to Swiss stocks have innovative ‘lock-in’ feature
|
9/14/2015 | SP | New Issue: Morgan Stanley prices $4.28 million worst-of lock-in RevCons linked to Swiss stocks
|
9/11/2015 | SP | Morgan Stanley plans 4.8%-5.1% worst-of lock-in RevCons tied to stocks
|
2/18/2014 | IG | New Issue: Novartis Capital prices $4 billion notes in 10-, 30-year tranches
|
2/18/2014 | IG | Novartis Capital intends to price offering of 10-, 30-year notes
|
2/18/2014 | IG | Market Commentary: Novartis, Illinois Tool, PG&E lead $7.25 billion session; Ryder firms; Novartis eases
|
2/8/2013 | IG | Moody's downgrades Novartis
|
9/19/2012 | IG | Market Commentary: Midday Commentary: 'Avalanche' of new issues continues; Novartis two-tranche deal tightens
|
9/19/2012 | IG | New Issue: Novartis Capital gives terms of $2 billion sale of notes in 10-, 30-year tranches
|
9/19/2012 | IG | Market Commentary: JPMorgan, Vodafone, Franklin Resources keep deal flow alive; Church & Dwight, Novartis firm
|
9/18/2012 | IG | Market Commentary: Novartis, ING, Westpac, Total, NextEra among names in packed primary; banks, brokers mixed
|
9/18/2012 | IG | Novartis Capital prepares $2 billion offering of 10-, 30-year notes
|
9/18/2012 | IG | Novartis files automatic shelf registration to issue debt securities
|
11/9/2011 | IG | Fitch: Novartis view to stable
|
12/16/2010 | IG | Fitch: Novartis view to negative
|
12/16/2010 | IG | Moody's affirm Novartis
|
3/22/2010 | IG | Market Commentary: Duke Energy, Florida Power/Progress, Rabobank offer bonds; health names trade mixed post-bill
|
1/4/2010 | IG | Market Commentary: National Australia Bank sells two tranches, EIB, Dexia Credit plan bond sales; spreads firm
|
12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
7/14/2009 | SS | Market Commentary: Noven deal may trigger Novartis interest; Exelon likely to bid again; IPC stock spread grows
|
7/14/2009 | SS | Market Commentary: Noven deal may trigger Novartis interest; Exelon likely to bid again; IPC stock spread grows
|
6/25/2009 | IG | Market Commentary: Citigroup, Jefferies, Analog Devices, MassMutual, Torchmark sell notes; Merck busy, up again
|
4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
2/6/2009 | IG | Market Commentary: Morgan Stanley, Citigroup tap primary; Caterpillar bonds falter; Altria gains; long bonds popular
|
2/5/2009 | IG | Market Commentary: Caterpillar Financial, Goldman Sachs sell bonds; new Altria, Novartis, CME gain; P&G notes flat
|
2/4/2009 | IG | New Issue: Novartis prices $5 billion of notes in five-, 10-year tranches
|
2/4/2009 | IG | Market Commentary: Novartis, Georgia Power, CME Group, Petrobras sell bonds, Novartis, Georgia Power trade up
|
2/3/2009 | IG | Novartis to price notes Wednesday in five-, 10-year tranches
|
2/3/2009 | IG | Market Commentary: Altria Group, P&G, Sunoco, Harley-Davidson, KfW sell bonds, Novartis plans issue
|
2/3/2009 | IG | Market Commentary: Altria Group, P&G, Sunoco, Harley-Davidson, KfW sell bonds, Novartis plans issue
|
1/9/2009 | SS | Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
|
9/26/2008 | CVIG | Novartis files automatic shelf registration
|
2/21/2008 | SP | New Issue: Bear Stearns prices $2.2 million 12.25% reverse convertibles linked to Novartis
|
2/19/2008 | SP | Bear Stearns to price 12.25% reverse convertibles linked to Novartis
|
9/21/2006 | BT | Novartis, Daiichi to end OTC medicine contract in December
|
9/19/2006 | BT | Novartis: Glivec approved in E.U. for leukemia, solid cancer tumor
|
9/18/2006 | BT | Novartis: Reclast highly effective in reducing osteoporosis fractures
|
9/18/2006 | BT | Cell Therapeutics, Novartis to develop Xyotax in lung cancer
|
9/14/2006 | BT | Crucell, Novartis to evaluate antibodies using STAR technology
|
9/14/2006 | BT | Novartis: Galvus lowers blood sugar with fewer side effects
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/13/2006 | BT | Novartis says FTY720 reduces multiple sclerosis relapses by 50%
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
8/30/2006 | BT | Novartis' Exjade gains E.U. approval for treatment of blood transfusional iron overload
|
8/22/2006 | BT | Entelos, Novartis agree to research collaboration using PhysioLab platforms, virtual patients
|
8/17/2006 | BT | Novartis seeks European approval for once-daily Galvus for treatment of type 2 diabetes
|
8/14/2006 | BT | Schering-Plough, Novartis to develop once-daily inhaled combination therapy for asthma, COPD
|
8/11/2006 | BT | Novartis: Femara endorsed by NICE for postmenopausal women with early breast cancer
|
8/8/2006 | BT | Sandoz', Momenta's generic Lovenox challenged by Aventis
|
8/8/2006 | BT | InVentiv Health signs multi-year sales team agreement with Novartis
|
7/28/2006 | BT | Novartis receives FDA approval for Famvir to treat recurrent genital herpes
|
7/28/2006 | BT | Novartis receives positive EU opinion for use of Glivec
|
7/26/2006 | BT | Novartis: Myfortic reduces gastrointestinal problems in two-thirds of renal-transplant patients
|
7/25/2006 | BT | Momenta, Sandoz collaborate to develop follow-on and generic drugs
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/24/2006 | BT | Novartis study shows Neoral more effective than tacrolimus in reducing diabetes after kidney transplant
|
7/19/2006 | BT | Gilead to acquire Corus Pharma for $365 million; Novartis to drop Corus lawsuit
|
7/19/2006 | BT | Novartis says study shows effectiveness of Exelon Patch in treating Alzheimer's disease symptoms
|
7/17/2006 | BT | Novartis group sales up 15% to $17.5 billion, pharmaceutical net sales up 17%
|
6/27/2006 | BT | Novartis given FDA approval of Exelon for Parkinson's disease
|
6/26/2006 | BT | MorphoSys, Novartis expand therapeutic antibody collaboration through 2011
|
6/26/2006 | BT | Novartis seeks Japanese approval of Xolair for asthma
|
6/23/2006 | BT | Teva: Novartis' Sandoz unit seeks to delay first FDA approval of generic Zocor
|
6/14/2006 | BT | Novartis' Tasigna shows 92% response rate in patients with treatment-resistant leukemia
|
6/13/2006 | BT | Novartis: Rasilez shows superior efficacy to ACE inhibitor ramipril in diabetes, high blood pressure
|
6/13/2006 | BT | Novartis expands late-stage vaccine pipeline with Intercell agreement
|
6/13/2006 | BT | Novartis say Galvus reduces blood sugar by 2.8% in patients with poor glycemic control
|
6/12/2006 | BT | Barr settles Warfarin sodium case for $22.5 million
|
6/9/2006 | BT | Novartis' Lotrel 5/40 mg and 10/40 mg dosage strengths approved
|
6/7/2006 | BT | Novartis offers to buy NeuTec for £305 million
|
6/5/2006 | BT | Genelabs to collaborate with Novartis on hepatitis C non-nucleoside drug candidates
|
6/5/2006 | BT | Novartis' leukemia tablet Gleevec shows increased response rate, decrease in disease progression
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
5/31/2006 | BT | Novartis unit Sandoz gets U.S. approval for Omnitrope as generic treatment for growth disorders
|
5/23/2006 | BT | Novartis to lead malaria research project in newly created public-private partnership
|
5/23/2006 | BT | Novartis data shows overactive bladder therapy Enablex does not impair memory function
|
5/22/2006 | BT | Novartis: study indicates Zelnorm may be safe, effective treatment for IBS with mixed bowel pattern
|
5/19/2006 | BT | Biovail to promote Novartis' Lescol products in Canada
|
5/19/2006 | BT | Novartis: Studies show blood pressure drug Diovan lowers C-reactive protein, an important inflammation marker
|
5/17/2006 | BT | Speedel, Novartis: Phase 3 data on SPP100 to treat hypertension shows potential for first-in-class drug
|
5/17/2006 | BT | Novartis' Exelon recommended for approval by FDA advisory committee
|
5/10/2006 | BT | Novartis: Gleevac becomes first oncology drug to target specific cause of cancer
|
5/4/2006 | BT | HHS awards more than $1 billion to five pharmaceutical companies to develop flu vaccines
|
5/1/2006 | BT | Idenix says lower dose of valopicitabine shows comparable antiviral activity as higher dose
|
5/1/2006 | BT | FDA approves higher dose formulations of Novartis' Diovan HCT for high blood pressure
|
4/27/2006 | BT | Novartis says New Drug Application for blood pressure drug Exforge accepted for review by FDA
|
4/20/2006 | BT | New Drug Application for high blood pressure drug Rasilez accepted for review by FDA
|
4/18/2006 | BT | Sandoz receives European Commission marketing authorization for Omnitrope
|
4/10/2006 | BT | Novartis completes submissions in United States, Europe for Gleevec as cancer treatment
|
4/6/2006 | BT | Results of extended phase 2 trial support Novartis' FTY720 as a treatment for MS
|
4/3/2006 | BT | Novartis raises Chiron bid to $48 per share
|
3/30/2006 | BT | Novartis: FDA accepts for review New Drug Application for Galvus to treat type 2 diabetes
|
3/29/2006 | BT | Novartis, Servier form licensing agreement for novel antidepressant
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/28/2006 | BT | SGX to collaborate with Novartis to develop treatment for chronic myelogenous leukemia
|
3/27/2006 | BT | Idenix, Novartis say telbivudine suppresses hepatitis B virus better than lamivudine
|
3/24/2006 | BT | Novartis' Zelnorm not approved in Europe
|
3/23/2006 | BT | Novartis says Femara shows benefit after prolonged period of no treatment
|
3/20/2006 | BT | Novartis drug Femara wins approval in Germany; new clinical trial planned
|
3/3/2006 | BT | Novartis' Famvir speeds healing time of cold sores, genital herpes, study says
|
3/2/2006 | BT | Idenix, Novartis amend terms for license of Idenix hepatitis C drug
|
2/27/2006 | BT | Novartis gets FDA approvable letter for Paget's disease treatment
|
2/21/2006 | BT | Market Commentary: Alnylam up 10% on Novartis pact; OSI off; CuraGen clipped; Inspire comes in; Ista drops despite data
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/9/2006 | BT | Bausch & Lomb, Novartis to co-promote Retisert
|
2/7/2006 | BT | Idenix, Novartis seek European approval of telbivudine to treat chronic hepatitis B
|
1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
1/19/2006 | BT | Speedel says Novartis releases positive phase 3 results for SPP100 in hypertension
|
1/18/2006 | BT | Ablynx collaborates with Novartis to develop Nanobody-based therapeutics
|
1/10/2006 | BT | Novartis says it's not interested in acquiring Berna while Crucell's bid to buy the vaccines maker progresses
|
1/3/2006 | BT | Idenix, Novartis submit NDA for 600 mg telbivudine to treat hepatitis B
|
12/30/2005 | BT | FDA approves Novartis' Femara for new breast cancer indication
|
12/20/2005 | BT | Market Commentary: Connetics rebounds to end higher; SeraCare plunges 48%; OraSure gains 8%; CuraGen rises by 4%
|
12/19/2005 | BT | Novartis considers buying vaccines-maker Berna to combine with other acquisition target Chiron
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/16/2005 | BT | Novartis drops development of NKS104 cholesterol drug
|
12/13/2005 | BT | Novartis' Femara decreases recurrence, metastasis of breast cancer in phase 3 study
|
12/12/2005 | BT | Fitch affirms Novartis
|
12/12/2005 | BT | Novartis: Gleevec study in myeloid leukemia patients shows 90.3% survival rate
|
12/8/2005 | BT | Chiron completes sale of $300 million of stock to Novartis
|
12/6/2005 | BT | Novartis buys licensing for Astex investigational agents in cancer research alliance
|
11/16/2005 | BT | Novartis asked to provide more data on use of Certican in heart transplants
|
11/16/2005 | BT | Novartis study screening shows high occurrence of cardiovascular disease in those with metabolic risks
|
11/14/2005 | BT | Study results on Novartis/Idenix drug Telbivudine shows significant suppression of hepatitis B virus
|
11/3/2005 | BT | Jefferies ups Novartis to buy
|
10/31/2005 | BT | Chiron agrees to be acquired by Novartis for $5.1 billion after price raised
|
10/25/2005 | BT | Jefferies maintains Novartis at hold
|
10/18/2005 | BT | Merrill Lynch maintains Novartis at neutral
|
9/6/2005 | BT | Chiron says Novartis' $4.5 billion offer for remaining shares 'inadequate'
|
9/1/2005 | BT | Novartis offers $40 per share for remainder of Chiron
|
9/1/2005 | BT | Moody's affirms Novartis
|
9/1/2005 | BT | Fitch affirms Novartis
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
7/18/2003 | CV | Barclays removes Friends Provident, adds Old Mutual, KfW/Deutsche Telekom
|
7/2/2003 | CV | New Issue: Swedish sells €75 million exchangeable, into Novartis, at 0.25%, up 22%
|
7/1/2003 | CV | Swedish Export €50 million exchangeable, into Novartis, talked to yield 0.25%, up 21-24%
|